Joyce Obeng, Maya Jetha, Jane Wrigley, Simon Jiang, Jason King, Bryan Miller, Rajendra Kumari, Yinfei Yin
Orthotopic syngeneic models provide a more clinically relevant tumor microenvironment for immuno-oncology drug development studies. This includes an organ-specific tumor location, which allows metastasis, and also recapitulates immune and stromal component tumor interactions.
Bioluminescent imaging (BLI) enables real-time, non-invasive longitudinal monitoring of orthotopic tumor burden and end stage quantification of tumor spread.
This poster details the generation of a panel of bioluminescent syngeneic cell lines for orthotopic and metastatic modeling. These models allow the assessment of standard of care agents, immune checkpoint therapies, and combination regimens in a more clinically relevant environment.